PharmaKure Limited Information

Over 50 milllion people worldwide are living with Alzheimer's disease. This is expected to increase to over 150 million by 2050. The associated health and social costs are expected to reach £1.5 trillion globally by 2030. While hundreds of drugs have been tested over the past decades, no cure has yet been found. PharmaKure have developed a unique screening approach to identify existing approved drugs which show activity as amyloid disaggregators. The misfolding of amyloid proteins in the brain is hypothesised to be a cause of Alzheimer's, with the oligomer forms being particularly toxic, so a disaggregating drug shows real promise as a therapeutic. This screening platform has identified two drugs showing significant activity in combination. These have been patented as repurposed drugs for Alzheimer's Disease, and are ready for Phase II clinical trials. Furthermore, our diagnostics partners have developed a unique method for the detection of Alzheimer's biomarkers. This allows for selection of a precise subject group in trials, in addition to providing a method for monitoring the trial, using whole blood samples. With this repurposed drug combination, and companion diagnostic, PharmaKure are joining the fight against Alzheimer's. PharmaKure Limited is based at the Manchester Science Park, UK.